Cargando…

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals

Objective: Chronic kidney disease (CKD) has significant effects on renal clearance of drugs. The application of antibiotics in CKD patients to achieve the desired therapeutic effect is challenging. This study aims to determine meropenem plasma exposure in the CKD population and further investigate o...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Guoliang, Yang, Fan, Sun, Ning, Liang, Danhong, Cen, Anfen, Zhang, Chen, Ni, Suiqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027930/
https://www.ncbi.nlm.nih.gov/pubmed/36959849
http://dx.doi.org/10.3389/fphar.2023.1126714
_version_ 1784909822246780928
author Deng, Guoliang
Yang, Fan
Sun, Ning
Liang, Danhong
Cen, Anfen
Zhang, Chen
Ni, Suiqin
author_facet Deng, Guoliang
Yang, Fan
Sun, Ning
Liang, Danhong
Cen, Anfen
Zhang, Chen
Ni, Suiqin
author_sort Deng, Guoliang
collection PubMed
description Objective: Chronic kidney disease (CKD) has significant effects on renal clearance of drugs. The application of antibiotics in CKD patients to achieve the desired therapeutic effect is challenging. This study aims to determine meropenem plasma exposure in the CKD population and further investigate optimal dosing regimens. Methods: A healthy adult PBPK model was established using the meropenem’s physicochemical parameters, pharmacokinetic parameters, and available clinical data, and it was scaled to the populations with CKD and dialysis. The differences between the predicted concentration, C(max), and AUC(last) predicted and observed model values were assessed by mean relative deviations (MRD) and geometric mean fold errors (GMFE) values and plotting the goodness of fit plot to evaluate the model’s performance. Finally, dose recommendations for CKD and hemodialysis populations were performed by Monte Carlo simulations. Results: The PBPK models of meropenem in healthy, CKD, and hemodialysis populations were successfully established. The MRD values of the predicted concentration and the GMFE values of C(max) and AUC(last) were within 0.5–2.0-fold of the observed data. The simulation results of the PBPK model showed the increase in meropenem exposure with declining kidney function in CKD populations. The dosing regimen of meropenem needs to be further adjusted according to the renal function of CKD patients. In patients receiving hemodialysis, since meropenem declined more rapidly during the on-dialysis session than the off-dialysis session, pharmacodynamic evaluations were performed for two periods separately, and respective optimal dosing regimens were determined. Conclusion: The established PBPK model successfully predicted meropenem pharmacokinetics in patients with CKD and hemodialysis and could further be used to optimize dosing recommendations, providing a reference for personalized clinical medication.
format Online
Article
Text
id pubmed-10027930
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100279302023-03-22 Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals Deng, Guoliang Yang, Fan Sun, Ning Liang, Danhong Cen, Anfen Zhang, Chen Ni, Suiqin Front Pharmacol Pharmacology Objective: Chronic kidney disease (CKD) has significant effects on renal clearance of drugs. The application of antibiotics in CKD patients to achieve the desired therapeutic effect is challenging. This study aims to determine meropenem plasma exposure in the CKD population and further investigate optimal dosing regimens. Methods: A healthy adult PBPK model was established using the meropenem’s physicochemical parameters, pharmacokinetic parameters, and available clinical data, and it was scaled to the populations with CKD and dialysis. The differences between the predicted concentration, C(max), and AUC(last) predicted and observed model values were assessed by mean relative deviations (MRD) and geometric mean fold errors (GMFE) values and plotting the goodness of fit plot to evaluate the model’s performance. Finally, dose recommendations for CKD and hemodialysis populations were performed by Monte Carlo simulations. Results: The PBPK models of meropenem in healthy, CKD, and hemodialysis populations were successfully established. The MRD values of the predicted concentration and the GMFE values of C(max) and AUC(last) were within 0.5–2.0-fold of the observed data. The simulation results of the PBPK model showed the increase in meropenem exposure with declining kidney function in CKD populations. The dosing regimen of meropenem needs to be further adjusted according to the renal function of CKD patients. In patients receiving hemodialysis, since meropenem declined more rapidly during the on-dialysis session than the off-dialysis session, pharmacodynamic evaluations were performed for two periods separately, and respective optimal dosing regimens were determined. Conclusion: The established PBPK model successfully predicted meropenem pharmacokinetics in patients with CKD and hemodialysis and could further be used to optimize dosing recommendations, providing a reference for personalized clinical medication. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10027930/ /pubmed/36959849 http://dx.doi.org/10.3389/fphar.2023.1126714 Text en Copyright © 2023 Deng, Yang, Sun, Liang, Cen, Zhang and Ni. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Deng, Guoliang
Yang, Fan
Sun, Ning
Liang, Danhong
Cen, Anfen
Zhang, Chen
Ni, Suiqin
Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
title Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
title_full Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
title_fullStr Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
title_full_unstemmed Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
title_short Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
title_sort physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in ckd and hemodialysis individuals
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027930/
https://www.ncbi.nlm.nih.gov/pubmed/36959849
http://dx.doi.org/10.3389/fphar.2023.1126714
work_keys_str_mv AT dengguoliang physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals
AT yangfan physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals
AT sunning physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals
AT liangdanhong physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals
AT cenanfen physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals
AT zhangchen physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals
AT nisuiqin physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals